Browsing Tag
Bristol Myers Squibb
58 posts
Why Bristol Myers Squibb is walking away from its first China joint venture after four decades
Bristol Myers Squibb’s 60% stake sale in its China JV shows a pivot from generics to innovation. Find out what this means for its stock and growth outlook.
LOTTE BIOLOGICS secures third major contract of 2025 through new U.S. biopharma manufacturing deal
LOTTE BIOLOGICS wins a third U.S. contract in 2025, boosting its CDMO momentum and investor sentiment. Find out how the deal shapes biomanufacturing strategy.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?
Can Pfizer’s oncology and rare disease pipeline replace billions lost to patent cliffs? Explore how the drugmaker compares with Merck, Bristol Myers, and AstraZeneca.
Bristol Myers Squibb Gains U.S. FDA Approval to Remove REMS Programs and Ease Monitoring Rules for Breyanzi and Abecma Cell Therapies
Bristol Myers Squibb gains U.S. FDA approval to remove REMS and reduce monitoring for Breyanzi and Abecma cell therapies, expanding access for blood cancer patients.
Checkpoint inhibitors in early-stage cancer: A new era of adjuvant therapy is taking shape
Checkpoint inhibitors are redefining early-stage cancer care. Find out how Tecentriq, Keytruda, and others are competing for the adjuvant immunotherapy market.
Biotech layoffs 2025: Prothena joins the wave—What’s driving the restructuring trend?
Explore why Prothena’s layoffs reflect a growing 2025 biotech downsizing trend. What’s causing the wave, and who might be next?
Why Alzheimer’s partnerships with Roche, BMS, and Novo Nordisk still matter for Prothena
Explore how Prothena’s strategic collaborations with Roche, BMS, and Novo Nordisk could shape the future of Alzheimer’s drug development.
Prothena halts birtamimab development after Phase 3 AFFIRM-AL trial fails to meet endpoints
Prothena ends birtamimab development after failed Phase 3 trial in AL amyloidosis. Find out how this impacts its pipeline, financials, and future direction.
Bristol Myers Squibb’s Opdualag fails to meet primary endpoint in Phase 3 trial
Bristol Myers Squibb has announced that its Phase 3 RELATIVITY-098 clinical trial, designed to evaluate Opdualag (nivolumab and…